Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (104)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Rosell, R.
Right arrow Articles by Gallant, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rosell, R.
Right arrow Articles by Gallant, G.
Related Collections
Right arrow 2002 - Editors Choice
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 13:1539-1549, 2002
© 2002 European Society for Medical Oncology

Original Paper

Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial

R. Rosell1,+, U. Gatzemeier2, D. C. Betticher3, U. Keppler4, H. N. Macha5, R. Pirker6, P. Berthet7, J. L. Breau8, P. Lianes9, M. Nicholson10, A. Ardizzoni11, A. Chemaissani12, J. Bogaerts13 and G. Gallant14

1 Hospital Germans Trias i Pujol Hospital, Badalona, Spain; 2 Grosshansdorf Hospital, Grosshansdorf, Germany; 3 Inselspital, Bern, Switzerland; 4 Fachklinik für Lungenkrankheiten, Immenhausen; 5 Lungenklinik Hemer, Hemer, Germany; 6 Department of Internal Medicine, University of Vienna, Vienna, Austria; 7 Centre François Baclesse, Caen; 8 Hopital Avicenne, Bobigny, France; 9 Hospital Universitario 12 de Octubre, Madrid, Spain; 10 Aberdeen Royal Infirmary, Aberdeen, UK; 11 Istituto dei Tumori, Genova, Italy; 12 Köln-Merheim Lungenklinik, Köln, Germany; 13 Bristol-Myers Squibb, Waterloo, Belgium; 14 Bristol-Myers Squibb, Wallingford, CT, USA

Received 27 March 2002; revised 3 June 2002; accepted 15 July 2002

Background:

The combination of paclitaxel with cisplatin or carboplatin has significant activity in non-small-cell lung cancer (NSCLC). This phase III study of chemotherapy-naïve advanced NSCLC patients was designed to assess whether response rate in patients receiving a paclitaxel/carboplatin combination was similar to that in patients receiving a paclitaxel/cisplatin combination. Paclitaxel was given at a dose of 200 mg/m2 (3-h intravenous infusion) followed by either carboplatin at an AUC of 6 or cisplatin at a dose of 80 mg/m2, all repeated every 3 weeks. Survival, toxicity and quality of life were also compared.

Patients and methods:

Patients were randomised to receive one of the two combinations, stratified according to centre, performance status, disease stage and histology. The primary analyses of response rate and survival were carried out on response-evaluable patients. Survival was also analysed for all randomised patients. Toxicity analyses were carried out on all treated patients.

Results:

A total of 618 patients were randomised. The two treatment arms were well balanced with regard to gender (83% male), age (median 58 years), performance status (83% ECOG 0–1), stage (68% IV, 32% IIIB) and histology (38% squamous cell carcinoma). In the paclitaxel/carboplatin arm, 306 patients received a total of 1311 courses (median four courses, range 1–10 courses) while in the paclitaxel/cisplatin arm, 302 patients received a total of 1321 courses (median four courses, range 1–10 courses). In only 76% of courses, carboplatin was administered as planned at an AUC of 6, while in 96% of courses, cisplatin was given at the planned dose of 80 mg/m2. The response rate was 25% (70 of 279) in the paclitaxel/carboplatin arm and 28% (80 of 284) in the paclitaxel/cisplatin arm (P = 0.45). Responses were reviewed by an independent radiological committee. For all randomised patients, median survival was 8.5 months in the paclitaxel/carboplatin arm and 9.8 months in the paclitaxel/cisplatin arm [hazard ratio 1.20, 90% confidence interval (CI) 1.03–1.40]; the 1-year survival rates were 33% and 38%, respectively. On the same dataset, a survival update after 22 months of additional follow-up yielded a median survival of 8.2 months in the paclitaxel/carboplatin arm and 9.8 months in the paclitaxel/cisplatin arm (hazard ratio 1.22, 90% CI 1.06–1.40; P = 0.019); the 2-year survival rates were 9% and 15%, respectively. Excluding neutropenia and thrombocytopenia, which were more frequent in the paclitaxel/carboplatin arm, and nausea/vomiting and nephrotoxicity, which were more frequent in the paclitaxel/cisplatin arm, the rate of severe toxicities was generally low and comparable between the two arms. Overall quality of life (EORTC QLQ-C30 and LC-13) was also similar between the two arms.

Conclusions:

This is the first trial comparing carboplatin and cisplatin in the treatment of advanced NSCLC. Although paclitaxel/carboplatin yielded a similar response rate, the significantly longer median survival obtained with paclitaxel/cisplatin indicates that cisplatin-based chemotherapy should be the first treatment option.

Key words: carboplatin, cisplatin, doublets, non-small-cell lung cancer, paclitaxel


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 ChestHome page
H. West, D. Harpole, and W. Travis
Histologic Considerations for Individualized Systemic Therapy Approaches for the Management of Non-small Cell Lung Cancer
Chest, October 1, 2009; 136(4): 1112 - 1118.
[Abstract] [Full Text] [PDF]

Home page
 Proc Am Thorac SocHome page
G. K. Dy and A. A. Adjei
Emerging Therapeutic Targets in Non-Small Cell Lung Cancer
Proceedings of the ATS, April 15, 2009; 6(2): 218 - 223.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
J-P. Sculier and D. Moro-Sibilot
First- and second-line therapy for advanced nonsmall cell lung cancer
Eur. Respir. J., April 1, 2009; 33(4): 915 - 930.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
B. Besse and T. Le Chevalier
Adjuvant Chemotherapy for Non-Small-Cell Lung Cancer: A Fading Effect?
J. Clin. Oncol., November 1, 2008; 26(31): 5014 - 5017.
[Full Text] [PDF]

Home page
 The OncologistHome page
S. Ramalingam and C. Belani
Systemic Chemotherapy for Advanced Non-Small Cell Lung Cancer: Recent Advances and Future Directions
Oncologist, January 1, 2008; 13(suppl_1): 5 - 13.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
P. A. Bunn Jr. and N. Thatcher
Conclusion
Oncologist, January 1, 2008; 13(suppl_1): 37 - 46.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
D. -W. Kim, S. -Y. Kim, H. -K. Kim, S. -W. Kim, S. W. Shin, J. S. Kim, K. Park, M. Y. Lee, and D. S. Heo
Multicenter phase II trial of Genexol-PM, a novel Cremophor-free, polymeric micelle formulation of paclitaxel, with cisplatin in patients with advanced non-small-cell lung cancer
Ann. Onc., December 1, 2007; 18(12): 2009 - 2014.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. Simon, A. Sharma, X. Li, T. Hazelton, F. Walsh, C. Williams, A. Chiappori, E. Haura, T. Tanvetyanon, S. Antonia, et al.
Feasibility and Efficacy of Molecular Analysis-Directed Individualized Therapy in Advanced Non-Small-Cell Lung Cancer
J. Clin. Oncol., July 1, 2007; 25(19): 2741 - 2746.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
A. Ardizzoni, L. Boni, M. Tiseo, F. V. Fossella, J. H. Schiller, M. Paesmans, D. Radosavljevic, A. Paccagnella, P. Zatloukal, P. Mazzanti, et al.
Cisplatin- Versus Carboplatin-Based Chemotherapy in First-Line Treatment of Advanced Non-Small-Cell Lung Cancer: An Individual Patient Data Meta-analysis
J Natl Cancer Inst, June 6, 2007; 99(11): 847 - 857.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
M. C. Garassino, L. Hollander, V. Torri, G. R. Oxnard, J.-P. Sculier, A.-P. Meert, M. Paesmans, G. Sonpavde, A. Sandler, R. Gray, et al.
Bevacizumab for Non-Small-Cell Lung Cancer
N. Engl. J. Med., March 29, 2007; 356(13): 1373 - 1375.
[Full Text] [PDF]

Home page
 Ann OncolHome page
P Bidoli, N Zilembo, D Cortinovis, L Mariani, L Isa, E Aitini, D Cullura, F Pari, P Nova, M Mancin, et al.
Randomized phase II three-arm trial with three platinum-based doublets in metastatic non-small-cell lung cancer. An Italian Trials in Medical Oncology study
Ann. Onc., March 1, 2007; 18(3): 461 - 467.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
T. Y. Seiwert, P. P. Connell, A. M. Mauer, P. C. Hoffman, C. M. George, L. Szeto, R. Salgia, K. E. Posther, B. Nguyen, D. J. Haraf, et al.
A Phase I Study of Pemetrexed, Carboplatin, and Concurrent Radiotherapy in Patients with Locally Advanced or Metastatic Non-Small Cell Lung or Esophageal Cancer
Clin. Cancer Res., January 15, 2007; 13(2): 515 - 522.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. Bepler, I. Kusmartseva, S. Sharma, A. Gautam, A. Cantor, A. Sharma, and G. Simon
RRM1 Modulated In Vitro and In Vivo Efficacy of Gemcitabine and Platinum in Non-Small-Cell Lung Cancer
J. Clin. Oncol., October 10, 2006; 24(29): 4731 - 4737.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
R. Booton, P. Lorigan, H. Anderson, S. Baka, L. Ashcroft, M. Nicolson, M. O'Brien, D. Dunlop, K. O'Byrne, V. Laurence, et al.
A phase III trial of docetaxel/carboplatin versus mitomycin C/ifosfamide/cisplatin (MIC) or mitomycin C/vinblastine/cisplatin (MVP) in patients with advanced non-small-cell lung cancer: a randomised multicentre trial of the British Thoracic Oncology Group (BTOG1)
Ann. Onc., July 1, 2006; 17(7): 1111 - 1119.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. Paccagnella, F. Oniga, A. Bearz, A. Favaretto, M. Clerici, F. Barbieri, A. Riccardi, A. Chella, U. Tirelli, G. Ceresoli, et al.
Adding Gemcitabine to Paclitaxel/Carboplatin Combination Increases Survival in Advanced Non-Small-Cell Lung Cancer: Results of a Phase II-III Study
J. Clin. Oncol., February 1, 2006; 24(4): 681 - 687.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
C. P. Belani, J. S. Lee, M. A. Socinski, F. Robert, D. Waterhouse, K. Rowland, R. Ansari, R. Lilenbaum, and R. B. Natale
Randomized phase III trial comparing cisplatin-etoposide to carboplatin-paclitaxel in advanced or metastatic non-small cell lung cancer
Ann. Onc., July 1, 2005; 16(7): 1069 - 1075.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
I. Okamoto, E. Moriyama, S. Fujii, H. Kishi, M. Nomura, E. Goto, C. Kiyofuji, F. Imamura, T. Mori, and M. Matsumoto
Phase II Study of Carboplatin-Paclitaxel Combination Chemotherapy in Elderly Patients with Advanced Non-small Cell Lung Cancer
Jpn. J. Clin. Oncol., April 1, 2005; 35(4): 188 - 194.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
G. V. Scagliotti, C. Kortsik, G. G. Dark, A. Price, C. Manegold, R. Rosell, M. O'Brien, P. M. Peterson, D. Castellano, G. Selvaggi, et al.
Pemetrexed Combined with Oxaliplatin or Carboplatin as First-Line Treatment in Advanced Non-Small Cell Lung Cancer: A Multicenter, Randomized, Phase II Trial
Clin. Cancer Res., January 15, 2005; 11(2): 690 - 696.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R.M. Rudd, N.H. Gower, S.G. Spiro, T.G. Eisen, P.G. Harper, J.A.H. Littler, M. Hatton, P.W.M. Johnson, W.M.C. Martin, E.M. Rankin, et al.
Gemcitabine Plus Carboplatin Versus Mitomycin, Ifosfamide, and Cisplatin in Patients With Stage IIIB or IV Non-Small-Cell Lung Cancer: A Phase III Randomized Study of the London Lung Cancer Group
J. Clin. Oncol., January 1, 2005; 23(1): 142 - 153.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
K. Hotta, K. Matsuo, H. Ueoka, K. Kiura, M. Tabata, and M. Tanimoto
Meta-Analysis of Randomized Clinical Trials Comparing Cisplatin to Carboplatin in Patients With Advanced Non-Small-Cell Lung Cancer
J. Clin. Oncol., October 1, 2004; 22(19): 3852 - 3859.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
D. J. Kerr
A word in your ear: the 2004 Annals of Oncology prizes
Ann. Onc., September 1, 2004; 15(9): 1303 - 1304.
[Full Text] [PDF]

Home page
 JAMAHome page
C. Delbaldo, S. Michiels, N. Syz, J.-C. Soria, T. Le Chevalier, and J.-P. Pignon
Benefits of Adding a Drug to a Single-Agent or a 2-Agent Chemotherapy Regimen in Advanced Non-Small-Cell Lung Cancer: A Meta-analysis
JAMA, July 28, 2004; 292(4): 470 - 484.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
J. D. Winegarden, A. M. Mauer, G. A. Otterson, C. M. Rudin, M. A. Villalona-Calero, V. J. Lanzotti, L. Szeto, K. Kasza, P. C. Hoffman, and E. E. Vokes
A phase II study of oxaliplatin and paclitaxel in patients with advanced non-small-cell lung cancer
Ann. Onc., June 1, 2004; 15(6): 915 - 920.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
T. L. Evans
Highlights from the Tenth World Conference on Lung Cancer
Oncologist, April 1, 2004; 9(2): 232 - 238.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
A. Spira and D. S. Ettinger
Multidisciplinary Management of Lung Cancer
N. Engl. J. Med., January 22, 2004; 350(4): 379 - 392.
[Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
H. Watanabe, N. Yamamoto, T. Tamura, T. Shimoyama, K. Hotta, A. Inoue, M. Sawada, Y. Akiyama, H. Kusaba, H. Nokihara, et al.
Study of Paclitaxel and Dose Escalation of Cisplatin in Patients with Advanced Non-small Cell Lung Cancer
Jpn. J. Clin. Oncol., December 1, 2003; 33(12): 626 - 630.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
F. Fossella, J. R. Pereira, J. von Pawel, A. Pluzanska, V. Gorbounova, E. Kaukel, K. V. Mattson, R. Ramlau, A. Szczesna, P. Fidias, et al.
Randomized, Multinational, Phase III Study of Docetaxel Plus Platinum Combinations Versus Vinorelbine Plus Cisplatin for Advanced Non-Small-Cell Lung Cancer: The TAX 326 Study Group
J. Clin. Oncol., August 15, 2003; 21(16): 3016 - 3024.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. H. Schiller
Platin or No Platin? That Is the Question
J. Clin. Oncol., August 15, 2003; 21(16): 3009 - 3010.
[Full Text] [PDF]

Home page
 Ann OncolHome page
J.-C. Soria and T. Le Chevalier
Is cisplatin still the best platinum compound in non-small-cell lung cancer?
Ann. Onc., October 1, 2002; 13(10): 1515 - 1517.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.